EN DE
Watch SANOFI CONS HEALTHC IND L for free: we tell you when fair value or trend changes.
Data-driven stock valuation

SANOFI CONS HEALTHC IND L (SANOFICONR) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of SANOFI CONS HEALTHC IND L stock ₹3,899, price ₹3,619, upside +7.7%, quality 89 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE0UOS01011

SC SANOFI CONS HEALTHC IND L logo Broad data Nov 12, 2026

SANOFI CONS HEALTHC IND L

SANOFICONR · NSE

Strong company, but the stock is already about fairly priced and falling price: meets 1 of 3 rules.

Get notified free when this changes
Quality 89/100 
Healthy Growth (revenue YoY +22.6 %/yr in INR) 
Highly profitable · 28.0% net margin (TTM) 
Generates free cash flow 
Broad data 
88% return on equity. 
Fair value ₹3,899 · Fairly valued 
Mixed vs. peers (6/13) 
Wide moat 92/100 · thin data
Falling price (downtrend) 
Quality growth
Watch SANOFI CONS HEALTHC IND L for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹5,610 ₹3,208 Fair Value ₹3,899 Sep 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.

How to read this chart

26‑month range ₹3,208 – ₹5,610 · fair‑value band ₹2,479 – ₹4,801 · the ₹3,619 price screens below the ₹3,899 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 12, 2026.

Follow SANOFI CONS HEALTHC IND L in your weekly email

Every Wednesday you see whether SANOFI CONS HEALTHC IND L is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India.

Show moreShow less

The company offers products in the allergy, physical wellness, and pain care segments under Allegra, Combiflam, Avil, DePURA, Festal, and other brand names through distributors, wholesalers, government institutions and hospitals, pharmacy chains, and e-commerce platforms.

The company was incorporated in 2023 and is based in Mumbai, India. Sanofi Consumer Healthcare India Limited operates as a subsidiary of Opella Healthcare Participations B.V.

Stock analysis

SANOFI CONS HEALTHC IND L (SANOFICONR) currently trades at ₹3,619, while our model-based Fair Value estimate is ₹3,899, so the stock looks roughly fairly valued today (gap 7.1%).

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹3,370 per share, and 1 of the 26 models we run sit above the ₹3,619 price.

Bear case: the Dividend Discount group reads lowest at ₹634.91, and 25 of the 26 models stay below the price. Data coverage for this calculation is high.

Scenario range: ₹2,479 (bear) to ₹4,801 (bull), the price of ₹3,619 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 89/100 (high quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

SANOFI CONS HEALTHC IND L reported revenue of ₹8.8B in FY2025 versus ₹5.4B in FY2023, a compound +27.0%/yr. Reported net income was ₹2.4B in FY2025, compounding +20.7%/yr from FY2023.

Key figures

Market cap ₹83.2B (≈ $883M) Small · P/E ratio 31.3 · P/S ratio 8.74 · EPS (TTM) ₹115.49 · Dividend yield 1.7% · Net margin 28.0% · Return on equity 88.0% · Return on assets (EBIT) 59.7% (3-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 92 out of 100 (low confidence).

What moves the price

The share trades about 27% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at 8%, SANOFICONR screens cheaper than that median.

Fair Value models

Bear ₹2,479 Fair Value ₹3,899 Bull ₹4,801
Price ₹3,619 · Upside +7.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then (₹101.25 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV ₹843.53 ₹926.20 ₹993.45 70
FCF DCF ₹1,111 ₹1,497 ₹2,625 69
Growth DCF ₹1,051 ₹1,561 ₹2,472 67
All 26 models by family
DCF Models
FCF DCF ₹1,111 ₹1,497 ₹2,625 69
Owner Earnings ₹1,102 ₹2,016 ₹3,621 64
5Y Revenue Exit ₹1,051 ₹1,681 ₹2,988 61
5Y EBITDA Exit ₹1,407 ₹2,403 ₹4,346 62
5Y P/E Exit ₹1,608 ₹3,449 ₹5,956 59
10Y Revenue Exit ₹1,041 ₹1,983 ₹2,595 58
10Y EBITDA Exit ₹1,291 ₹2,635 ₹5,054 56
10Y P/E Exit ₹1,417 ₹3,003 ₹5,717 52
Earnings-Based
Graham-Dodd ₹708.92 ₹4,944 ₹6,938 57
Lynch FV ₹1,941 ₹2,773 ₹3,604 55
PEG = 1.0 ₹1,941 ₹2,773 ₹3,604 52
EPV ₹843.53 ₹926.20 ₹993.45 70
Dividend Discount
Gordon GGM ₹387.20 ₹652.71 ₹851.31 62
DDM Multi-Stage ₹387.20 ₹617.10 ₹701.81 61
Multiples
P/E Multiple ₹1,720 ₹2,294 ₹2,867 63
P/S Multiple ₹1,001 ₹1,335 ₹1,669 58
P/B Multiple ₹561.56 ₹748.74 ₹935.93 55
EV/EBIT ₹1,798 ₹2,347 ₹2,895 63
EV/EBITDA ₹1,561 ₹2,031 ₹2,500 64
EV/Revenue ₹953.10 ₹1,296 ₹1,640 51
Asset-Based
NCAV (Graham) ₹94.94 ₹143.85 ₹179.81 52
Growth DCF
Growth DCF ₹1,051 ₹1,561 ₹2,472 67
Rev-Margin DCF ₹1,051 ₹1,898 ₹3,424 60
Economic Profit
Residual Income ₹489.45 ₹771.49 ₹1,861 61
ROIC Compounder ₹846.70 ₹933.07 ₹1,005 64
Growth Earnings
Growth-Adj P/E ₹2,359 ₹3,370 ₹4,381 61

Open the full fair value analysis →

Quality Score breakdown

Overall quality 89/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 100
How much profit the company makes from its sales and capital
Quality Growth 52
Are margins and returns getting better?
Cashflow 70
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 84
How calm the share price moves, does not count
Price momentum 14
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 15
Distance to the 52-week high, does not count
New shares 83
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+31.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +26.5% a year for the price.

Watch SANOFICONR, get fair value alerts →

Compare SANOFI CONS HEALTHC IND L with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks

Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 89 · Top 25%
Fair Value upside +8.0% · Above median
Profitability
Return on equity (12 months) 88.0% · Top 25%
Return on assets 43.9% · Top 25%
Net margin (12 months) 28.0% · Top 25%
Operating margin (12 months) 36.5% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 6.7% · Below median
Dividend yield (12 months) 1.7% · Below median

Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper

P/E (12 months) 31.3× · Pricier than median
P/B 21.62× · Priciest 25%
P/S (12 months) 8.74× · Priciest 25%
Price / free cash flow (fiscal year) 46.0× · Priciest 25%
EV/EBITDA 22.9× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)44 · sector 22
FUTURE (revenue growth)34 · sector 35
PAST (return on equity)100 · sector 43
HEALTH (low debt)0 · sector 92
DIVIDEND (yield)33 · sector 37

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Bristol-Myers Squibb Company BMY $63.43 $75.91 +20% vs SANOFICONR
Amgen Inc AMGN $465.67 $512.24 +10% vs SANOFICONR
Gilead Sciences, Inc GILD $168.08 $184.89 +10% vs SANOFICONR
Novartis AG NOVN CHF 134.06 CHF 122.91 −8% vs SANOFICONR
AbbVie Inc ABBV $295.03 $259.62 −12% vs SANOFICONR
Merck & Co MRK $147.76 $129.26 −13% vs SANOFICONR
Pfizer Inc PFE $28.89 $24.87 −14% vs SANOFICONR
Roche Holding RO CHF 412.00 CHF 326.56 −21% vs SANOFICONR
Johnson & Johnson, JNJ $285.75 $169.03 −41% vs SANOFICONR
Eli Lilly and Company LLY $1,444 $749.92 −48% vs SANOFICONR

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SANOFI CONS HEALTHC IND L: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "SANOFI CONS HEALTHC IND L Fair Value". https://www.fairvalue-calculator.com/stock/SANOFICONR

Frequently asked questions

Is SANOFI CONS HEALTHC IND L (SANOFICONR) overvalued or undervalued?
As of Nov 12, 2026, our model estimates a fair value of ₹3,899 versus a price of ₹3,619, about +8% upside (fairly valued).
What is the fair value of SANOFICONR?
Our model-based fair value for SANOFI CONS HEALTHC IND L is ₹3,899 (as of Nov 12, 2026), built from audited fundamentals. The current price: ₹3,619.
What is the quality score of SANOFICONR?
SANOFI CONS HEALTHC IND L has a Quality Score of 89/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SANOFI CONS HEALTHC IND L (SANOFICONR)?
Our model-based price target is the fair value of ₹3,899 (as of Nov 12, 2026) from 26 valuation models. Cautious scenario ₹2,479, optimistic scenario ₹4,801. It is a calculation from audited fundamentals, not an analyst target.
What is the SANOFI CONS HEALTHC IND L stock forecast for 2026?
Our models put fair value at ₹3,899, about +8% upside versus a price of ₹3,619 (fairly valued). Cautious scenario ₹2,479, optimistic scenario ₹4,801. The calculation is refreshed regularly with new filings.
What is the revenue of SANOFI CONS HEALTHC IND L (SANOFICONR)?
SANOFI CONS HEALTHC IND L reported trailing-twelve-month revenue of about ₹9.5B (latest available figure, as of Nov 12, 2026).
Does SANOFI CONS HEALTHC IND L pay a dividend?
SANOFI CONS HEALTHC IND L currently shows a dividend yield of 1.65% relative to its recent price (as of Nov 12, 2026).
How much is the dividend of SANOFI CONS HEALTHC IND L (SANOFICONR)?
SANOFI CONS HEALTHC IND L has a dividend yield of 1.7%.
What growth is priced into SANOFI CONS HEALTHC IND L (SANOFICONR)?
For today's price to be fair in a discounted-cash-flow model, SANOFI CONS HEALTHC IND L would have to grow free cash flow by 31.7 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 2 years revenue grew 27.0 % per year. As of Nov 12, 2026.
What discount rate (WACC) does the fair value of SANOFICONR use?
Our models discount SANOFI CONS HEALTHC IND L at 12.4 %: a base by market capitalisation (small), damped by beta 0.27, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For SANOFI CONS HEALTHC IND L that is +31.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has SANOFI CONS HEALTHC IND L (SANOFICONR) delivered so far?
Over the past 2 years revenue at SANOFI CONS HEALTHC IND L grew 27.0 % a year. The price currently implies free-cash-flow growth of +31.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of SANOFI CONS HEALTHC IND L (SANOFICONR) growing?
The median revenue growth in the sector is +4.4 % a year. That is the yardstick for the growth priced into SANOFI CONS HEALTHC IND L (+31.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of SANOFI CONS HEALTHC IND L (SANOFICONR)?
The free-cash-flow yield on the price is 2.17 %: that much free cash flow SANOFI CONS HEALTHC IND L produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of SANOFI CONS HEALTHC IND L (SANOFICONR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SANOFI CONS HEALTHC IND L it is ₹3,899 per share (as of Nov 12, 2026), against a price of ₹3,619. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is SANOFI CONS HEALTHC IND L stock overvalued or undervalued in 2026?
As of Nov 12, 2026, SANOFICONR trades below its calculated fair value: price ₹3,619, fair value ₹3,899, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SANOFICONR?
No. The price is what the market pays today (₹3,619); the fair value is what the company's own numbers justify (₹3,899). For SANOFI CONS HEALTHC IND L the two are ₹280.16 per share apart. That gap is exactly why we show both numbers side by side.
How much is SANOFI CONS HEALTHC IND L worth?
The market values SANOFI CONS HEALTHC IND L at about ₹83.2B (market capitalisation, as of Nov 12, 2026). Per share that is ₹3,619; our models calculate a fair value of ₹3,899 per share.
What do the bullish and bearish scenarios say about SANOFICONR?
Our models span a range for SANOFI CONS HEALTHC IND L: cautious scenario ₹2,479, base ₹3,899, optimistic ₹4,801 per share (as of Nov 12, 2026, price ₹3,619). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SANOFICONR?
SANOFI CONS HEALTHC IND L trades at a price-to-earnings ratio of 31.3 (as of Nov 12, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹3,899 is built from several models across several years. Other multiples: P/B 21.6, P/S 8.7, EV/EBITDA 22.9.
How solid is the balance sheet of SANOFI CONS HEALTHC IND L (SANOFICONR)?
Balance-sheet figures for SANOFI CONS HEALTHC IND L (as of Nov 12, 2026): return on equity 88.0%. They feed the Quality Score of 89/100, which measures business quality independently of the share price.
How far is SANOFICONR from its 52-week high?
SANOFI CONS HEALTHC IND L trades at ₹3,619, about 27% below its 52-week high of ₹4,951 and 13% above the low of ₹3,208 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹3,899 is for.
Which stocks are comparable to SANOFI CONS HEALTHC IND L?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SANOFI CONS HEALTHC IND L stock attractive at the current price?
The data as of Nov 12, 2026: price ₹3,619, calculated fair value ₹3,899 (+8%), Quality Score 89/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SANOFICONR calculated?
We run SANOFI CONS HEALTHC IND L through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹3,899 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. SANOFI CONS HEALTHC IND L currently trades 7% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SANOFI CONS HEALTHC IND L (SANOFICONR)?
The closing price on Nov 16, 2026 was ₹3,619. Our model-based fair value is ₹3,899, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SANOFI CONS HEALTHC IND L right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (₹2,479 to ₹4,801) leaves room in how you read the outcome.

Key figures of SANOFI CONS HEALTHC IND L

How large is the market capitalisation of SANOFI CONS HEALTHC IND L (SANOFICONR)?
The market capitalisation of SANOFI CONS HEALTHC IND L is ₹83.2B (≈ $883M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SANOFI CONS HEALTHC IND L (SANOFICONR)?
The price-to-sales ratio of SANOFI CONS HEALTHC IND L is 8.74 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SANOFI CONS HEALTHC IND L (SANOFICONR)?
Earnings per share at SANOFI CONS HEALTHC IND L are ₹115.49 (price ÷ EPS = P/E 31.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of SANOFI CONS HEALTHC IND L (SANOFICONR)?
The dividend yield of SANOFI CONS HEALTHC IND L is 1.7% (payout 51.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of SANOFI CONS HEALTHC IND L (SANOFICONR)?
The net margin of SANOFI CONS HEALTHC IND L is 28.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SANOFI CONS HEALTHC IND L (SANOFICONR)?
The return on equity (ROE) of SANOFI CONS HEALTHC IND L is 88.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SANOFI CONS HEALTHC IND L (SANOFICONR)?
On an EBIT basis the return on assets of SANOFI CONS HEALTHC IND L is 59.7% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SANOFI CONS HEALTHC IND L (SANOFICONR)?
The operating margin of SANOFI CONS HEALTHC IND L is 36.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SANOFI CONS HEALTHC IND L (SANOFICONR)?
Revenue at SANOFI CONS HEALTHC IND L is growing 6.7% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SANOFI CONS HEALTHC IND L (SANOFICONR)?
Earnings per share at SANOFI CONS HEALTHC IND L are growing 13.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does SANOFI CONS HEALTHC IND L (SANOFICONR) hold?
SANOFI CONS HEALTHC IND L holds more cash than debt, ₹3.5B net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch SANOFI CONS HEALTHC IND L in the live analysis

One click puts SANOFI CONS HEALTHC IND L on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.